Early detection of cancer is critical for improving patient outcomes and decreasing mortality. In this collection of CME-accredited activities, expert faculty discuss the latest professional recommendations for cancer screening and strategies for overcoming barriers to screening, particularly among underserved populations. Further, faculty will examine emerging testing technologies such as blood- and stool-based tests that detect tumor DNA with greater sensitivity and specificity than currently available tests. Other programs in this collection will cover novel technologies for other cancer types, such as liquid biopsy blood tests that can detect residual disease in patients with early-stage CRC, breast, and lung cancers.
Disclaimer
The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.
Medscape Education© Medscape, LLC